Drug profile · INN
ambrisentan
AMBRISENTAN VIATRIS
ambrisentan (AMBRISENTAN VIATRIS) is a endothelin receptor, et-a/et-b antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — ambrisentan
- US status
- approved
- Class
- Cardiovascular system (C02)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
ambrisentan (AMBRISENTAN VIATRIS) is a endothelin receptor, et-a/et-b antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Endothelin receptor, ET-A/ET-B antagonist
Primary target: Endothelin receptor, ET-A/ET-B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ambrisentan?
ambrisentan (AMBRISENTAN VIATRIS) is a endothelin receptor, et-a/et-b antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ambrisentan?
AMBRISENTAN VIATRIS is a marketed brand name for ambrisentan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ambrisentan?
ambrisentan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.